What is MOTS-c?
MOTS-c is a 16-amino-acid peptide studied as a mitochondrial signal. Its metabolic research is frequently discussed alongside exercise and aging.
Video overview · 2:44
MOTS-c: Is It Really "Exercise in a Pill"? What the Research Shows
Where the mitochondrial peptide comes from, how it acts on the cell's energy sensor, the mouse studies behind the hype, why no published study has given it to people, and its FDA, compounding and anti-doping status.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
MOTS-c is a small peptide your own mitochondria make, and online it is marketed as exercise in a pill. The mouse results are striking. But no published study has given it to people. Here is what is actually known.
MOTS-c is sixteen amino acids long and, unusually, it is encoded in your mitochondrial DNA rather than the cell's main DNA. It acts mainly on muscle, where it switches on AMPK, a cellular energy sensor that exercise also turns on. And exercise raises the body's own MOTS-c in muscle and blood.
Here is the idea. MOTS-c acts on muscle cells, switches on the AMPK energy sensor, and in mice, that protected against weight gain and helped them run longer. Whether it can stand in for exercise in people has never been tested.
In its 2015 discovery paper, MOTS-c protected mice from diet-induced obesity and insulin resistance. In 2021, it improved physical performance in young, middle-aged and old mice. And in a 2022 study, a single injection in untrained mice increased running time by twelve percent in one test. All of these are mouse results.
In people, studies have only measured the body's own MOTS-c, never given it as a treatment. In a randomized study of thirty people, it only trended up after endurance exercise. And the FDA says it has not identified any human exposure data for MOTS-c products.
MOTS-c is not FDA approved, and the World Anti-Doping Agency bans it by name. In July 2026, the FDA's compounding advisory committee voted seven to five to recommend allowing it for obesity and osteoporosis, against FDA staff advice, according to news reports. That vote is advisory, not an approval, and the FDA flags possible immune reactions and impurities.
Is MOTS-c exercise in a pill? Unproven: the results are from mice, with no human treatment trial. Does exercise raise it? The evidence is mixed: one study found it does, while a randomized study found only a trend. Is it safe? Unproven. And is it allowed in sport? No, it is banned by name.
The bottom line: MOTS-c is a real and interesting peptide your body makes, and in mice it acts a bit like exercise. But no published study has given it to people, its safety is unknown, and it is not approved. For every study and source, see the MOTS-c profile on PepsRadar dot com.
Biological role or research focus
Mitochondrial signaling and metabolic research.
Experiments in cells and mice do not establish exercise replacement or weight-loss outcomes in people.
Role reference: The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. ↗
Names you may encounter
MOTS C · MOTSC
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Mitochondrial-derived signaling peptide
- Main research area
- Metabolic stress responses
- Evidence featured
- Animal / laboratory study
- Source check
- October 4, 2026
Quick answers
- Is MOTS-c FDA approved?
- No. No FDA-approved drug contains MOTS-c. Source ↗
- Is MOTS-c safe?
- Unapproved mitochondrial peptide. FDA found no human exposure data and flagged immune-reaction and impurity risks; its safety in people is unknown. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
- Is MOTS-c banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S4.4.1 Metabolic modulators (AMPK activators)). Source ↗
- Has the FDA taken action over MOTS-c?
- Yes. Our records list 2 FDA actions naming it, most recently on October 28, 2026: HHS filed an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (Federal Register 2026-22192, published October 30, 2026; RIN 0910-ZD94). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Metabolic homeostasis study (2015) | Animal / laboratory study | Cell systems and mouse models of aging or high-fat feeding. |
| Exercise-associated signaling and mouse physical performance (2021) | Human observations + mouse experiments | Human exercise observations, cultured muscle cells, and young, middle-aged, and old mice. |
Claim check
Unproven Is MOTS-c really exercise in a pill?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Animal / laboratory study · 2015
Metabolic homeostasis study
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
- Population / model
- Cell systems and mouse models of aging or high-fat feeding.
- Study design
- Mechanistic metabolic assays and treatment experiments in mice.
- Main finding
- MOTS-c affected folate/purine metabolism and AMPK signaling; treated mice were protected against some insulin-resistance and obesity phenotypes.
- Limits & context
- A mitochondrial origin does not establish a safe supplement or exercise replacement. This study did not test clinical weight loss or diabetes outcomes in humans.
Human observations + mouse experiments · 2021
Exercise-associated signaling and mouse physical performance
Were people given MOTS-c, or was their own peptide measured after exercise?
- Population / model
- Human exercise observations, cultured muscle cells, and young, middle-aged, and old mice.
- Study design
- The human component measured endogenous MOTS-c responses to exercise; administration experiments and late-life treatment were performed in mice.
- Main finding
- Exercise increased endogenous MOTS-c in human muscle and circulation. In mice, administered MOTS-c improved reported physical-performance measures across age groups; late-life experiments examined physical capacity and healthspan.
- How to read it
- The human observations and mouse interventions answer different questions. An exercise-associated biomarker change does not show that injecting the peptide improves human fitness.
- Limits & context
- The abstract does not report a randomized human MOTS-c treatment trial. Mouse physical-capacity or healthspan results cannot be relabeled as human lifespan extension.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
2 registered studies name MOTS-c as an intervention; 1 is recruiting or under way, 0 have not started recruiting yet, 0 completed and 1 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation NCT07678073 · University of Gaziantep | Recruiting | Not applicable | 2026-03-01 | 68 |
| Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD NCT04027712 · University of Athens | Status unknown | 2014-01-01 | 120 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination.
Related records in our PubMed snapshot
MOTS-c in sepsis-induced cardiomyopathy: Mechanisms and translational potential. ↗
European journal of pharmacology · Issue date 2026 Oct 15 · Not appraised
MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation. ↗
Autophagy · Issue date 2026 Oct · Not appraised
Risks & interactions
Unapproved mitochondrial peptide. FDA found no human exposure data and flagged immune-reaction and impurity risks; its safety in people is unknown.
No published human safety studies were found. Human research measured the body's own MOTS-c after exercise; giving the peptide has been tested only in cells and mice. FDA says it lacks information on whether it would cause harm in people.
Unassessed: no human safety data
It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Serious risks
- Possible immune reactions (immunogenicity) and peptide impurities, per FDA's compounding safety listing
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Bulk drug substances that may present significant safety risks ↗ · MOTS-c promotes metabolic homeostasis (Cell Metab, 2015) ↗ · MOTS-c is an exercise-induced regulator of physical decline (2021) ↗
Safety evidence & remaining uncertainty
FDA reports a human-exposure evidence gap. Endogenous signaling does not establish the safety of externally administered commercial preparations.
Source: FDA · Peptide compounding safety concerns ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Formerly Category 2 (FDA flagged safety risks); nominations withdrawn
Was in 503A category 2 (significant safety risks) as "MOTs-C". The nominations were withdrawn by the nominators and FDA moved it to the "nominated but withdrawn" table (page updated April 22, 2026). It is not in category 1 and is not on the 503A bulks list. FDA presented MOTS-c (free base and acetate) to its Pharmacy Compounding Advisory Committee on July 23, 2026, proposing that it NOT be added to the 503A bulks list. On October 28, 2026, HHS filed an interim enforcement discretion policy covering MOTS-c (Federal Register 2026-22192): HHS does not intend to act against state-licensed pharmacies, federal facilities or licensed physicians compounding it while rulemaking proceeds. That is not listing on the 503A bulks list and not FDA approval. source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S4.4.1 Metabolic modulators (AMPK activators)
Named explicitly ("mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)"). source
FDA actions
- HHS filed an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (Federal Register 2026-22192, published October 30, 2026; RIN 0910-ZD94). MOTS-c is one of six peptides in its Appendix A (BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500). HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding with these peptides while FDA develops the 503A bulks list by rulemaking. It is not an FDA approval, does not add MOTS-c to the 503A bulks list, is not binding, and HHS may revisit it if a safety signal or quality problem arises. The comment period on regulations.gov closed on November 13, 2026 (docket HHS-OASH-2026-0496). (2026-10-28) source
- FDA presented MOTS-c (free base and acetate) to its Pharmacy Compounding Advisory Committee (July 23, 2026) for possible addition to the 503A bulks list; FDA's briefing document proposed NOT adding it. The committee's vote is advisory; no final FDA decision found. (2026-07) source
Other notes
- Canada, November 6, 2026: Health Canada warned consumers not to buy or inject unauthorized peptides sold online after lab tests of vials seized from a Chinese supplier found bacteria, including Acinetobacter seifertii, Acinetobacter nosocomialis and Cutibacterium acnes. It seized over 11,400 vials from the supplier and two Canadian online retailers, whose websites are no longer active. Unauthorized products sold as MOTS-c were among the example products listed. Authorized drugs for sale in Canada carry an 8-digit Drug Identification Number (DIN) on the label. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
The selected evidence is preclinical. It does not establish a human exercise substitute, weight-loss therapy, or treatment for diabetes.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
The original study connected MOTS-c with folate/purine metabolism and activation of AMPK, a cellular energy-sensing pathway. That mechanism was explored in cells and mice.
Molecular structure
Questions worth asking
- What specific product, route, and research population does the claim refer to?
- Does the source measure an outcome in people, or only a laboratory marker?
- Experiments in cells and mice do not establish exercise replacement or weight-loss outcomes in people.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Did this paper show that people could replace exercise?
No. That claim was not tested.
Does mitochondrial origin mean better energy in people?
It identifies a biological origin and hypothesis. Patient fatigue, exercise capacity, and long-term outcomes need clinical measurement.
What does the Exercise-associated signaling and mouse physical performance study show, and what does it not?
The human observations and mouse interventions answer different questions. An exercise-associated biomarker change does not show that injecting the peptide improves human fitness. The abstract does not report a randomized human MOTS-c treatment trial. Mouse physical-capacity or healthspan results cannot be relabeled as human lifespan extension.
References & editorial record
- FDA · Compounding safety concerns ↗
- MOTS-c metabolic study (2015) ↗
- Reynolds et al. · Nature Communications · 2021 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
From a promising mechanism to a useful finding
A practical way to read peptide research without turning an interesting experiment into a clinical promise.
Read the guide →RESEARCH FIELD GUIDE
MOTS-c and exercise: what happened in people, and what happened in mice
One paper can contain several kinds of evidence. An exercise-associated signal is different from a human treatment result.
Read the guide →RESEARCH FIELD GUIDE
Mitochondrial peptides: what MOTS-c, humanin and SS-31 (elamipretide) actually show in people
MOTS-c and humanin are made by mitochondria; elamipretide (SS-31) is a drug aimed at them. Mouse data and blood-level studies back the first two; only elamipretide has human trials and a narrow FDA approval.
Read the guide →RESEARCH FIELD GUIDE
Which peptides can pharmacies compound now? The 2026 HHS peptide policy explained
HHS says it will not act against licensed 503A compounders using six peptides while FDA writes its bulks-list rules. That is not FDA approval, and FDA staff found little or no human data for any of the six.
Read the guide →



